Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

19 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-01-04

Study Completion Date

2027-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inducing Systemic Immunity and Regressions in Metastatic Melanoma

NCT02350972

Metastatic Malignant Melanoma

COMPLETED PHASE1

Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma

NCT03683550

Melanoma

UNKNOWN NA

Identification of Metabolic Phenotypes Associated With Melanoma Metastasis

NCT06400550

Melanoma (Skin)

RECRUITING

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

NCT00055562

Melanoma Neoplasm Metastasis

COMPLETED PHASE2/PHASE3

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

NCT02828202

Malignant Melanoma

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Spontaneous regression in patients with metastatic cancer is an incredibly rare event. It has been described after infection in cancer patients and also rarely in patients with renal cell cancer (usually after resection of the renal primary) and, less commonly, in patients with metastatic melanoma.

Primary Objective To collect peripheral blood from patients with metastatic melanoma and renal cell cancer and spontaneous regression for studies of immune response and other studies.

Secondary Objective To collect clinical data from subjects registered to this study. Clinical data collection will include demographics and cancer characteristics, history and treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma; Renal Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spontaneous regression

Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.

Blood collection for laboratory studies

Intervention Type OTHER

Peripheral whole blood will be collected

Data collection from medical record

Intervention Type OTHER

Clinical data such as demographics and cancer characteristics, history and treatment will be collected

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood collection for laboratory studies

Peripheral whole blood will be collected

Intervention Type OTHER

Data collection from medical record

Clinical data such as demographics and cancer characteristics, history and treatment will be collected

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ≥ 18 years old at the time of informed consent
2. Ability to provide written informed consent and HIPAA authorization
3. Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
4. Willingness to undergo phlebotomy for research blood samples

Exclusion Criteria

1. Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety
2. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No